Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedAppWAR:MDA +2.89%42 Receivables Turnover is 2.57 as of Mar. 2026. GuruFocus rates WAR:MDA with a GF Score™ of 42/100 and a GF Value™ of zł0.24 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 660 Healthcare Providers & Services companies, MedApp ranks worse than 86.52% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. MedApp's Revenue for the
three
months ended in Mar. 2026 was zł2.96 Mil. MedApp's average Accounts Receivable for the
three
months ended in Mar. 2026 was zł1.15 Mil.
Hence, MedApp's Receivables Turnover for the
three
months ended in Mar. 2026 was 2.57.
MedApp (WAR:MDA) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
MedApp Receivables Turnover Related Terms
MedApp Receivables Turnover Historical Data
* Premium members only.
The historical data trend for MedApp's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:MDA vs VEEV, BTSG, TEM: Receivables Turnover Comparison
For the Health Information Services subindustry, MedApp's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MedApp Receivables Turnover vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, MedApp's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where MedApp's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MedApp (WAR:MDA) has a Receivables Turnover of 2.57 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on MedApp and its competitors. According to the industry distribution chart, MedApp ranks #571 out of 660 companies in the Healthcare Providers & Services industry, placing it in the top 86.5%.
Is MedApp's Receivables Turnover too high?
MedApp's current Receivables Turnover is 2.57. The Healthcare Providers & Services industry median Receivables Turnover is 7.75. MedApp's value of 2.57 is 66.8% below this industry median. Based on the distribution chart, MedApp ranks #571 out of 660 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, MedApp has a GF Score™ of 42/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does MedApp's Receivables Turnover compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, MedApp ranks #571 out of 660 companies for Receivables Turnover. This places MedApp in the lower half of its industry. The industry median Receivables Turnover is 7.75. MedApp's value of 2.57 is 66.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Healthcare Providers & Services company?
The median Receivables Turnover among Healthcare Providers & Services companies is 7.75, based on 660 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MedApp's current Receivables Turnover of 2.57 is 66.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on MedApp and its competitors. For the Healthcare Providers & Services industry, the median Receivables Turnover is 7.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MedApp's current Receivables Turnover is 2.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedApp stock overvalued right now?
Based on GuruFocus' analysis, MedApp (WAR:MDA) is currently considered Modestly Undervalued. The stock's GF Value™ is zł0.24, compared to a current price of zł0.20 — trading 18.3% below its estimated fair value. The current Receivables Turnover is 2.57 and 66.8% below the Healthcare Providers & Services industry median of 7.75. MedApp's overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For MedApp (WAR:MDA), the current Receivables Turnover is 2.57 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MedApp (WAR:MDA) Overvalued in 2026?
Based on GuruFocus' analysis, MedApp stock appears to be undervalued.
The current stock price of zł0.20 is trading 18.3% below its estimated GF Value™ of zł0.24.
GuruFocus considers MedApp to be Modestly Undervalued.
Key valuation signals for WAR:MDA:
Receivables Turnover: 2.57
GF Value™: zł0.24 vs. price of zł0.20 (18.3% below fair value)
Industry Position: 66.8% below the Healthcare Providers & Services median (#571 of 660)
No single metric tells the full story. See the WAR:MDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:MDA has been successfully added to your 
